High-Conviction CNS Disruptor Aiming to Transform Suicidal Depression, Ketamine Therapeutics, and TMS - Reaching Millions by 2030 Medical, Health, Marketing, Media, Financial
OKAVA Pharmaceuticals Announces First Cat Dosed in MEOW-1 Study of OKV-119, the World's First Clinical-Stage GLP-1 Weight-Loss Therapy for Pets San Francisco
FDA Accepts ANDA for KETAFREE™ as Analyst Sets $34 Price Target for NRx Pharmaceuticals: (N A S D A Q : NRXP) NRx is Poised for a massive Breakthrough Medical, Health, Marketing, Media, Financial
The ROS1ders Announces Recipients of the 2025 ROS1+ Cancer Innovation Award Sacramento, Medical, Health
Revenue Expansion, Regulatory Momentum, and a Leadership Position in the $750 Million Suicidal Depression: NRx Pharmaceuticals (N A S D A Q: NRXP) Medical, Health, Marketing, Media, Financial
$750 Million Market on Track to $3.35 Billion by 2034: $NRXP Launches First-in-Florida "One Day" Depression Treatment in Partnership with Ampa Health Medical, Health, Marketing, Media, Financial
$750 Million Market Set to Soar to $3.35 Billion by 2034 as Florida Launches First-in-Nation One-Day: NRx Pharmaceuticals (N A S D A Q: NRXP) $NRXP Medical, Health, Marketing, Media, Financial
U.S. Entrepreneur Anjo De Heus Builds Innovation Bridge Between America and the Gulf Business, Investment, Health, Technology, Artificial Intelligence
High-Conviction CNS Disruptor Aiming to Transform Suicidal Depression, Ketamine Therapeutics, and TMS - Reaching Millions by 2030
$750 Million Market Set to Soar to $3.35 Billion by 2034 as Florida Launches First-in-Nation One-Day: NRx Pharmaceuticals (N A S D A Q: NRXP) $NRXP
U.S. Entrepreneur Anjo De Heus Builds Innovation Bridge Between America and the Gulf
DERMA-CODE™ Announces Ingredient Transparency and Molecular Innovation in Skincare
Vesica Health Granted PLA Billing Code for AssureMDx